Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings
Rhea-AI Summary
Oncocyte Corp (Nasdaq: OCX), a diagnostics technology company, has announced its participation in 'J.P. Morgan Week' alongside the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco from January 13-16, 2025.
CEO Josh Riggs and CFO Andrea James will be available for one-on-one meetings with investors during the event. Interested investors can schedule meetings through Julie Silber at PCG Advisory.
Positive
- None.
Negative
- None.
News Market Reaction – OCX
In the trading session that priced this news, OCX gained 1.63%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
January 13-16, 2025, San Francisco, CA
IRVINE, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend “J.P. Morgan Week,” coinciding with the 43ʳᵈ Annual J.P. Morgan Healthcare Conference in San Francisco, from January 13-16, 2025. During this period, Oncocyte will host one-on-one meetings with interested investors.
Investors wishing to schedule a meeting are encouraged to contact Julie Silber at PCG Advisory via email at jsilber@pcgadvisory.com.
Event: “J.P. Morgan Week”
Dates: January 13-16, 2025
Location: San Francisco, CA, USA
About Oncocyte
Oncocyte is a diagnostics technology company. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test. GraftAssure™ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit https://oncocyte.com/. For more information about our products, please visit the following web pages:
VitaGraft Kidney™ – https://oncocyte.com/vitagraft-kidney/
VitaGraft Liver™ – https://oncocyte.com/vitagraft-liver/
GraftAssure™ – https://oncocyte.com/graftassure/
DetermaIO™ – https://oncocyte.com/determa-io/
DetermaCNI™ – https://oncocyte.com/determa-cni/
VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.
CONTACT:
Jeff Ramson
PCG Advisory
(646) 863-6893
jramson@pcgadvisory.com
